Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept + FOLFIRI in Previously Treated mCRC (AFEQT)
NCT01670721Phase 3Completed
- Sponsor
- Sanofi
- Start
- Aug 2012
- Primary completion
- Jun 2015
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of aflibercept in metastatic colorectal cancer (mCRC), sponsored by Sanofi. Primary endpoint: Percentage of Participants With Adverse Events. Started Aug 2012; status: completed.
02
Drugs
aflibercept
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01670721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01670721.